Filarial DiseasesTranslation


  • Target disease: Filarial diseases
  • Main partners (since project start): Abbvie, USA; AWOL, UK; Liverpool School of Hygiene & Tropical Medicine, UK; University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology, Germany.
  • Start date: March 2015
  • Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; USAID, USA. 


Overall Objective:

  • Develop ABBV-4083 as an anti-Wolbachia therapy and assess its macrofilaricidal efficacy


ABBV-4083 is a derivative of tylosin, a veterinary antibiotic that targets the worm-symbiont Wolbachia. The compound is currently in clinical development for the treatment of filarial diseases. ABBV-4083 is orally available, induces a robust anti-Wolbachia effect in several in vivo models, demonstrates clear superiority over doxycycline, and is effective after a shorter dosing regimen. Preliminary safety and toxicology profiling of this compound suggest a favourable safety profile.


The Phase I study, that took place at AbbVie’s Clinical Pharmacology Research Unit, was completed in 2018; the results support progression to Phase II.

Toxicology studies were completed in 2017, and an oral formulation was developed. In December, AbbVie began the first human trial of ABBV-4083 to test the drug’s safety in healthy volunteers and assist in the selection of doses for future trials. This Phase I study, conducted at at AbbVie’s Clinical Pharmacology Research Unit in Chicago, US is expected to be completed in 2018.

Preliminary safety and toxicology profiling of this compound suggests a favourable safety profile. Upon completion of toxicology studies and the development of an oral formulation, a Phase l study will be conducted in 2017. The aim will be to assess the safety, tolerability, and pharmacokinetics of ABBV-4083.


Last update: February 2019